Approximately 80% of breast cancers (BCs) express the estrogen receptor alpha (ERα), encoded by the ESR1 gene, and endocrine therapy (ET) with selective ER modulators (SERMs) or aromatase inhibitors (AIs) is the mainstay of treatment for this group of patients because of their effectiveness balanced against their side effects. This evidence concerns the gene ESR1 and breast carcinoma.